PLRX - Pliant Therapeutics Inc - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7291391057
Fibrosis, Integrin, Inhibitors, Pulmonary, Liver, Cancer, Muscular
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for fibrosis and related diseases. The company's research and development efforts are centered around creating novel therapies that can address the underlying causes of these debilitating conditions.
At the forefront of Pliant's pipeline is bexotegrast, an oral, small-molecule inhibitor that selectively targets avß6 and avß1 integrins. This lead candidate is currently in phase 2b clinical trials for idiopathic pulmonary fibrosis, a chronic and progressive lung disease, and in phase 2a trials for primary sclerosing cholangitis, a rare liver disease. By targeting these specific integrins, bexotegrast has the potential to slow or halt the progression of fibrosis, improving the quality of life for patients with these conditions.
In addition to bexotegrast, Pliant is developing a range of other promising therapies. PLN-1474, an oral, small-molecule inhibitor of avß1, is being developed to treat liver fibrosis associated with nonalcoholic steatohepatitis, a common liver disease. Meanwhile, PLN-101095, a dual inhibitor of avß8 and avß1 integrins, is being explored for its potential in treating solid tumors. The company is also investigating PLN-101325, a novel therapy for muscular dystrophies, a group of genetic disorders characterized by progressive muscle weakness and degeneration.
Founded in 2015, Pliant Therapeutics is headquartered in South San Francisco, California, and is committed to advancing its pipeline of innovative therapies through clinical development and commercialization. With a strong focus on fibrosis and related diseases, the company is poised to make a meaningful impact on the lives of patients and families affected by these conditions.
Drawdown (Underwater) Chart
PLRX Stock Overview
Market Cap in USD | 701m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2020-06-03 |
PLRX Stock Ratings
Growth 5y | -45.2 |
Fundamental | - |
Dividend | |
Rel. Performance vs Sector | -4.12 |
Analysts | 4.62/5 |
Fair Price Momentum | 15.43 USD |
Fair Price DCF | - |
PLRX Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
PLRX Growth Ratios
Growth Correlation 3m | 3.7% |
Growth Correlation 12m | -65.2% |
Growth Correlation 5y | -54.1% |
CAGR 5y | -7.83% |
CAGR/Mean DD 5y | -0.16 |
Sharpe Ratio 12m | 0.32 |
Alpha vs SP500 12m | -31.90 |
Beta vs SP500 5y weekly | 0.91 |
ValueRay RSI | 88.97 |
Volatility GJR Garch 1y | 57.59% |
Price / SMA 50 | 16.37% |
Price / SMA 200 | 8.63% |
Current Volume | 470.2k |
Average Volume 20d | 456.7k |
External Links for PLRX Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of October 29, 2024, the stock is trading at USD 14.86 with a total of 470,170 shares traded.
Over the past week, the price has changed by +1.36%, over one month by +31.39%, over three months by +7.06% and over the past year by +1.30%.
According to ValueRays Forecast Model, PLRX Pliant Therapeutics Inc will be worth about 17.1 in October 2025. The stock is currently trading at 14.86. This means that the stock has a potential upside of +14.94%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 40.2 | 170 |
Analysts Target Price | 46.6 | 213 |
ValueRay Target Price | 17.1 | 14.9 |